Trial Profile
A Phase 1, Open-label, Dose Escalation And Expansion Study Of Pf-06801591 In Patients With Locally Advanced Or Metastatic Melanoma, Squamous Cell Head And Neck Cancer, Ovarian Cancer, Sarcoma, Non-small Cell Lung Cancer, Urothelial Carcinoma Or Other Solid Tumors
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 25 Apr 2022
Price :
$35
*
At a glance
- Drugs Sasanlimab (Primary) ; Sasanlimab (Primary)
- Indications Adenocarcinoma; Endometrial cancer; Head and neck cancer; Malignant melanoma; Non-small cell lung cancer; Oesophageal cancer; Ovarian cancer; Peritoneal cancer; Renal cell carcinoma; Salivary gland cancer; Sarcoma; Small cell lung cancer; Solid tumours; Squamous cell cancer; Urogenital cancer
- Focus Adverse reactions; First in man; Therapeutic Use
- Sponsors Pfizer
- 18 Mar 2022 Data from patients of this study were used to develop population PK model for sasanlimab, presented at the 123rd Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics.
- 25 Oct 2021 Results (n=38) assessing whether tumor responses of sasanlimab were associated with baseline TMB, PD-L1, CD8, and IFN gene signature levels, across multiple dose levels, routes of administration and broad range of tumor types from a cohort published in the Targeted Oncology
- 15 Dec 2020 Status changed from active, no longer recruiting to completed.